

## **PHASE 1 PREVENTIVE HIV VACCINE TRIAL**

**A phase I double-blind, placebo-controlled, randomized trial to evaluate the safety and immunogenicity of TBC-M4, a multigenic MVA HIV vaccine vs ADVAX, a multigenic DNA HIV vaccine followed by TBC-M4**

The results of the first phase I HIV vaccine trial using a multigenic MVA vaccine conducted at this centre indicated that while this was safe and effective in inducing immune response in all the vaccine recipients, the persistence and the magnitude of the response should be improved before moving this vaccine further in human trials. Therefore, it was decided to use this in a prime-boost regimen involving a DNA vaccine (ADVAX) to prime and the MVA vaccine to boost. During the year under review, the necessary regulatory clearances were obtained and the laboratory procedures were standardized. The advocacy activities were initiated in March, 2009.

[Contact person: Dr.V.D.Ramanathan (E-Mail ID: ramanathanvd@trchennai.in)]